Key Insights

Highlights

Treatment Research

2 treatments under study, led by Paclitaxel

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 100/100

Termination Rate

100.0%

1 terminated out of 1 trials

Success Rate

0.0%

-86.6% vs benchmark

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

1 of 0 completed with results

Key Signals

1 with results0

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Terminated1

Clinical Trials (1)

Showing 1 of 1 trials
NCT00322881Phase 2Terminated

Carboplatin and Paclitaxel in Elderly Women With Newly Diagnosed Ovarian, Peritoneal, or Fallopian Cancer

Showing all 1 trials

Research Network

Common Treatments

  • Paclitaxel1
  • Carboplatin1

Active Sponsors

  • Dana-Farber Cancer Institute1
  • Massachusetts General Hospital1
  • Brigham and Women's Hospital1

Top Investigators

Related Conditions

  • Primary Peritoneal Carcinoma1
  • Fallopian Tube Cancer1
  • Ovarian Cancer1

Activity Timeline